From what I understand, Myriad's test involved synthesis of cDNA (which we scientists refer to as "complementary DNA", not "composite DNA" as SCOTUS does). This is still covered by the patent. However, any test based on sequencing the genomic DNA, for example, would not violate Myriad's patent. Genomic sequencing of these genes was previously a violation of the patent. This is definitely a step forward.
In the long run, Myriad is hosed because they no longer own the sequence, including analysis. Any diagnostic not using reverse transcription of the mRNA does not violate Myriad's patent. This includes synthesis of any non-cDNA polymer, such as XNA.